Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes

Amer M. Zeidan,Jui-Hua Tsai,Milad Karimi,Jordana Schmier,Sayeli Jayade,Evangelos Zormpas,Audrey Hassan,Desiree Ruiters, Cindy Anthony,Kala Hill,Tim Wert,Marc Botteman

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 2|浏览12

暂无评分

摘要

•Patients prioritized avoiding AML risk and fatigue over reduced administration burden•Most respondents (76.6%) were predicted to switch to an oral pill if available.

查看译文

关键词

Oral therapy,Drug administration routes,Hematologic neoplasms,Preferences,Hypomethylating agent

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要